Dr. Tananbaum uses a data-driven approach to make big bets in healthcare and life sciences
SAN FRANCISCO–(BUSINESS WIRE)–Foresite Capital, a cross-stage healthcare and life sciences investment firm, today announced that Dr. Jim Tananbaum, chief executive officer and managing director, has been named to Forbes’ Midas List of Top Tech Investors. Dr. Tananbaum was ranked #44, marking his fourth consecutive year and continued rise in position on the list.
Forbes’ Midas List recognizes the top 100 venture capitalists based on the number and size of exits over the past five years, with a premium on bolder early-stage deals. Since 2011, the list has been a partnership between Forbes and venture capital investment firm TrueBridge Capital Partners.
“It’s an honor to be named to the Midas List for another year, and I’d like to extend a huge thank you to my colleagues at Foresite Capital,” said Dr. Tananbaum. “Every member of our team has contributed to our outstanding investment results. Being on the Midas List four times in a row starting when Foresite Capital was only two years old is a great sign that we are building a durable investment franchise.”
Dr. Tananbaum founded Foresite Capital in 2011 to merge his entrepreneurial experience and networks gained from 25 years in healthcare investing. The ability to ingest and derive meaning from massive amounts of complex information is a critical success factor in healthcare investing, so Dr. Tananbaum brought together a multidisciplinary team of scientists, engineers, analysts, and clinicians who collaborate to make the best data-driven investment decisions. Throughout his career, he has excelled at systematic and deep technical analysis of healthcare opportunities, while supporting the growth of companies from small enterprises into enduring franchises, included funding major investments in companies like Jazz Pharmaceuticals, Amerigroup and 10x Genomics.
Earlier in Dr. Tananbaum’s career, he was the co-founder of GelTex Pharmaceuticals and Theravance which have brought several category leading drugs to market. He also co-founded Prospect Venture Partners II and III. He graduated from Yale University with BS/BSEE degrees and earned an M.D. and M.B.A. from Harvard University, and an M.S. from the Massachusetts Institute of Technology.
About Forbes’ Midas List
Forbes develops the Midas List of Top Tech Investors in partnership with TrueBridge Capital Partners by collecting data from publicly available sources, including Dow Jones VentureSource exit data and historical lists, and from direct submissions from venture capital firms. Then, Forbes calculates a ranking for each venture capitalist’s investment in a qualifying company based on generated deal value, size of exit or private valuation and other key metrics, and determines a deal metric ranking against his or her peers. A total deal count score, which determines the ranking by deal count for each venture capitalist, is also determined. Together, the rankings by deal metric and deal count, coupled with a review by experienced institutional investors and venture experts, determine a venture capitalist’s position on The Midas List.
About Foresite Capital
Established in 2011, Foresite Capital is a cross-stage healthcare and life sciences investment firm that applies rigorous scientific and data-driven approaches to investment analysis. The firm has $1.2 billion under management. Foresite Capital takes a collaborative approach to investing with a multidisciplinary team of scientists, engineers, analysts and clinicians who understand the unique business models in healthcare. The company aims to address areas of great unmet clinical need over the long term by funding promising healthcare and life sciences businesses at all stages of their life cycles. Its portfolio also emphasizes companies that are employing the tools of data science and machine intelligence in healthcare. Foresite Capital is based in San Francisco with an office in New York. For more information, please visit www.foresitecapital.com.